Compare · PACB vs RVTY
PACB vs RVTY
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $10.97B, about 24.4x PACB ($450.4M).
- PACB has been more active in the news (14 items in the past 4 weeks vs 2 for RVTY).
- PACB has more recent analyst coverage (24 ratings vs 19 for RVTY).
- Company
- Pacific Biosciences of California Inc.
- Revvity Inc.
- Price
- $1.45-10.80%
- $98.44-3.84%
- Market cap
- $450.4M
- $10.97B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 14
- 2
- Recent ratings
- 24
- 19
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest PACB
- SEC Form 4 filed by Director Mohr Marshall
- SEC Form 4 filed by Director Gibson Christopher
- SEC Form 4 filed by Director Smith Christopher M
- SEC Form 4 filed by Director Valantine Hannah
- SEC Form 4 filed by Director Livingston Randall S
- SEC Form 4 filed by Director Ericson William W.
- SEC Form 4 filed by Director Milligan John F
- SEC Form 4 filed by Director Ordonez Kathy
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Pacific Biosciences of California Inc.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)